DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Roxadustat" drug pipelines has been added to ResearchAndMarkets.com's offering.
Roxadustat (FibroGen/Astellas/AstraZeneca) is a hypoxia-inducible factor (HIF) prolyl-hydroxylase inhibitor in development for the treatment of anemia in chronic kidney disease. The drug is administered orally three times per week and mimics the body's natural response to reduced oxygen levels by increasing levels of HIFs. These factors are involved in erythropoiesis. Roxadustat treats anemia primarily by reducing hepcidin levels, increasing iron transport and absorption proteins, and stimulating erythropoietin production.
Key Topics Covered:
List of Figures
Figure 1: Roxadustat for anemia in chronic kidney disease - SWOT analysis
Figure 2: Drug assessment summary of roxadustat for anemia in chronic kidney disease
Figure 3: Drug assessment summary of roxadustat for anemia in chronic kidney disease
Figure 4: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
List of Tables
Table 1: Roxadustat drug profile
Table 2: Roxadustat Phase III trials in anemia in chronic kidney disease
Table 3: Roxadustat Phase II and III data in anemia in chronic kidney disease
Table 4: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/t3xcgb/roxadustat?w=4
